1. Home
  2. XAIR vs ARTL Comparison

XAIR vs ARTL Comparison

Compare XAIR & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beyond Air Inc.

XAIR

Beyond Air Inc.

BUY

Current Price

$2.16

Market Cap

3.0M

Sector

Health Care

ML Signal

BUY

ARTL

Artelo Biosciences Inc.

HOLD

Current Price

$2.77

Market Cap

2.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XAIR
ARTL
Founded
2011
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0M
2.5M
IPO Year
2015
2014

Fundamental Metrics

Financial Performance
Metric
XAIR
ARTL
Price
$2.16
$2.77
Analyst Decision
Buy
Analyst Count
2
0
Target Price
★ $20.00
N/A
AVG Volume (30 Days)
58.5K
★ 1.2M
Earning Date
11-09-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $7,679,000.00
N/A
Revenue This Year
$4.23
N/A
Revenue Next Year
$108.84
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 107.26
N/A
52 Week Low
$0.33
$0.52
52 Week High
$8.19
$179.19

Technical Indicators

Market Signals
Indicator
XAIR
ARTL
Relative Strength Index (RSI) 33.67 35.87
Support Level $0.44 $0.52
Resistance Level $2.66 $6.81
Average True Range (ATR) 0.24 0.23
MACD 0.00 -0.04
Stochastic Oscillator 17.02 2.22

Price Performance

Historical Comparison
XAIR
ARTL

About XAIR Beyond Air Inc.

Beyond Air Inc a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (NO) generators and delivery systems (the LungFit platform) capable of generating NO from ambient air. Its segments are Beyond Air, Beyond Cancer, and NeuroNos. The company generates majority of revenue from Beyond Air. It has developed the Beyond Air NO generator and delivery system which it call LungFit, a novel and precise delivery system that uses NO generated from ambient air with a novel NO generator, the ionizer. Its product and technology includes LungFitPH.

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

Share on Social Networks: